Nov 02, 2022 7:15am EDT Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
Oct 25, 2022 7:00am EDT Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
Oct 13, 2022 7:00am EDT Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
Sep 12, 2022 7:00am EDT Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
Aug 25, 2022 7:00am EDT Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
Aug 23, 2022 7:00am EDT Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Aug 22, 2022 7:00am EDT Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
Aug 17, 2022 7:25am EDT Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
Jul 11, 2022 7:00am EDT Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Jun 29, 2022 7:00am EDT Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
